ARMO BioSciences

📍 Redwood City, United States🗓 Founded 2012💰 Last funded Feb 2017
Biotechnology🌐 armobio.com
Website LinkedIn
ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. The Company’s lead product candidate, AM0010 (pegilodecakin, PEGylated Interleukin-10), has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types. The drug is currently being investigated in a Phase 3 randomized pivotal clinical trial in pancreatic cancer patients. ARMO also has a number of other immuno-oncology product candidates in various stages of pre-clinical development including: AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, form of recombinant human Interleukin-15 (IL-15); and AM0012, a form of recombinant human Interleukin-12 (IL-12).
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2012
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in ARMO BioSciences?
ARMO BioSciences has 1 investors on record on gritt.io, 1 mid-stage.
When did ARMO BioSciences last raise funding?
The most recent investment in ARMO BioSciences recorded on gritt.io was in February 2017.
When was ARMO BioSciences founded?
ARMO BioSciences was founded in 2012.
What industry is ARMO BioSciences in?
ARMO BioSciences operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is ARMO BioSciences based?
ARMO BioSciences is headquartered in Redwood City, United States.